Nafamostat Mesylate API

Name	Nafamostat mesylate
Chinese name	甲磺酸萘莫司他
Cas Number	82956-11-4
Source	India/Korea
Qualifications	-/-/-/-/-

Nafamostat mesylate is a synthetic protease inhibitor, developed by Japan Tobacco and first marketed in Japan in 1986. It is used for acute pancreatitis, acute exacerbation of chronic pancreatitis, and acute pancreatitis after pancreatography. Improvement of symptoms such as inflammation, traumatic pancreatitis, and acute pancreatitis after surgery. This product has a strong selective inhibitory effect on trypsin-like serine proteases such as trypsin, fibrinase, fibrinase, kallikrein (Kallikrein), and C1r, C1S in the classical pathway of the complement system. It also inhibits the trypsin that binds to a2-macroglobulin in vitro. It can also inhibit the increase in pancreatic enzyme activity caused by pancreatitis and the enzyme activity into the blood. Trypsin, enterokinase and endotoxin are injected retrogradely through the pancreatic duct All experimental pancreatitis caused by it can reduce its mortality. The relevant guidelines recommend adequate application in the early stage of acute pancreatitis, and the market prospects are good. Recently, the Medical Research Institute of the University of Tokyo has discovered that it has the effect of preventing the new coronavirus from entering human cells, and is expected to inhibit the proliferation of the virus in the body, and the effect will be better when used with other antiviral drugs.

Hot Tags: nafamostat mesylate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Solinasine Succinate API, Lurasidone Hydrochloride API, Ticagrelor API, Perindopril Arginine API, Vardenafil API, Dimethyl Fumarate API

• Previous: Suvorsen API
• Next: Lenvatinib Mesylate API